Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Other Accumulated Expenses (2021 - 2025)

Universe Pharmaceuticals' Other Accumulated Expenses history spans 5 years, with the latest figure at $54.7 million for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 62.88% to $54.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $54.7 million, a 62.88% decrease, with the full-year FY2025 number at $54.7 million, down 62.88% from a year prior.
  • Other Accumulated Expenses hit $54.7 million in Q3 2025 for Universe Pharmaceuticals, down from $147.4 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for UPC hit a ceiling of $147.4 million in Q3 2024 and a floor of $52263.0 in Q3 2022.
  • Historically, Other Accumulated Expenses has averaged $40.6 million across 5 years, with a median of $444319.0 in 2021.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 88.24% in 2022 and later soared 112404.1% in 2024.
  • Tracing UPC's Other Accumulated Expenses over 5 years: stood at $444319.0 in 2021, then tumbled by 88.24% to $52263.0 in 2022, then soared by 150.74% to $131045.0 in 2023, then soared by 112404.1% to $147.4 million in 2024, then plummeted by 62.88% to $54.7 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for UPC at $54.7 million in Q3 2025, $147.4 million in Q3 2024, and $131045.0 in Q3 2023.